Hematology

The pediatric oncology pharmacist at Mayo Clinic discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.

Review top news and interview highlights from the week ending February 23, 2024.

The medical director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed the pros and cons of potentially curative treatment options for SCD.

Differences between IEC and non-IEC post-relapse outcomes showed some significance in PFS but not in ORR.

The physician from St. Jude Children’s Research Hospital discussed the importance of involvement from patients and families while researching the long-term impact of CAR-T.

The assistant clinical director of the Center for Gene and Cellular Immunotherapy at Washington University in St. Louis discussed Atara Biotherapeutics' tabelecleucel and AlloVir’s posoleucel.

Patients with high bone marrow burden and CNS/non-CNS EMD were found to experience the worst OS and EFS outcomes.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The assistant professor of neurology at University of Washington, Seattle Children's discussed efforts to address a gap in knowledge in the long-term effects of CAR-T, if any, on children’s neurological development.

Promising data on OriCAR-017 were previously published in the Lancet Haematology in 2023.

The assistant professor at Mayo Clinic School of Medicine discussed the design of the phase 1 trial.

The director of Cell Therapy and Transplant at Penn Medicine discussed the potential of CAR T-cell therapy to benefit patients with diseases including Lupus nephritis.

Chris McDonald, senior vice president and global head of technical operations, Kite Pharma, discussed axi-cel's FDA approved manufacturing changes.

Review top news and interview highlights from the week ending February 16, 2024.

The approval follows the separate US approvals in December 2023 and January 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The director of the Adult Sickle Cell Clinic and associate professor at University of Alabama Birmingham pointed out access to a sickle cell specialist as one such priority.

Hemogenyx noted that the agency confirmed all issues pointed out in the initial clinical hold letter from June 2023 had been sufficiently addressed by the company.

The BAFFR-CAR T-cell therapy is being investigated in a phase 1 single-center and phase 1 multicenter trial in B-ALL and B-NHL.

The clinical assistant professor at Stanford Medicine discussed potential applications for machine learning in analyzing data in medicine.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The new Cell and Gene Therapy Access Model will be led by the Centers for Medicare & Medicaid Services’ Innovation Center.

The assistant professor at MD Anderson Cancer Center discussed a trial she is leading at MD Anderson with NK cells and cetuximab in colorectal cancer.

The professor in residence of pediatrics at University of California San Francisco discussed trends in research for SCD gene therapy.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive™ team.

For World Cancer Day, held annually on February 4, take a look at the stories that have stood out in oncology cell therapy so far this year.

Review top news and interview highlights from the week ending February 2, 2024.

The director of the Adult Sickle Cell Clinic and associate professor at University of Alabama Birmingham discussed work the National Alliance of Sickle Cell Centers is conducting.

Vor Bio recently also announced data from the phase 1/2 trial of trem-cel.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.